We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Chemed (CHE) Up 1.7% Since Last Earnings Report: Can It Continue?
Read MoreHide Full Article
A month has gone by since the last earnings report for Chemed (CHE - Free Report) . Shares have added about 1.7% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Chemed due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important drivers.
Chemed Tops Q2 Earnings & Revenue Estimates
Chemed Corporation reported second-quarter 2026 adjusted earnings per share of $6.06, up 41.9% year over year. The figure surpassed the Zacks Consensus Estimate by 9.2%.
The company’s GAAP earnings per share were $5.13, up 43.7% from last year’s reported figure.
CHE’s Q2 Revenues
Revenues in the reported quarter totaled $673.3 million, up 8.8% from the year-ago quarter’s figure. The metric topped the Zacks Consensus Estimate by 1.9%.
Chemed’s Raises 2026 Guidance
For 2026, the company now expects rVITAS revenue-growth guidance excluding Medicare Cap, to increase 8.25-9.25% (earlier 6.5-7.5%). The Zacks Consensus Estimate for total revenues is pegged at $2.67 billion, which indicates a 7.4% year-over-year improvement.
Adjusted EPS for the year is now expected to be in the band of $25.00-$25.75 (previously $24.00-$24.75). The Zacks Consensus Estimate for the metric is pegged at $25.00.
How Have Estimates Been Moving Since Then?
Analysts were quiet during the last two month period as none of them issued any earnings estimate revisions.
The consensus estimate has shifted 6.27% due to these changes.
VGM Scores
At this time, Chemed has a nice Growth Score of B, though it is lagging a bit on the Momentum Score front with a C. Following the exact same course, the stock has a score of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Chemed has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Chemed is part of the Zacks Medical - Outpatient and Home Healthcare industry. Over the past month, Quest Diagnostics (DGX - Free Report) , a stock from the same industry, has gained 4.2%. The company reported its results for the quarter ended June 2026 more than a month ago.
Quest Diagnostics reported revenues of $3.04 billion in the last reported quarter, representing a year-over-year change of +10.2%. EPS of $3.12 for the same period compares with $2.62 a year ago.
For the current quarter, Quest Diagnostics is expected to post earnings of $2.85 per share, indicating a change of +9.6% from the year-ago quarter. The Zacks Consensus Estimate has changed +1.1% over the last 30 days.
Quest Diagnostics has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of B.
View the Zacks #1 Rank List
Image: Bigstock
Chemed (CHE) Up 1.7% Since Last Earnings Report: Can It Continue?
A month has gone by since the last earnings report for Chemed (CHE - Free Report) . Shares have added about 1.7% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Chemed due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important drivers.
Chemed Tops Q2 Earnings & Revenue Estimates
Chemed Corporation reported second-quarter 2026 adjusted earnings per share of $6.06, up 41.9% year over year. The figure surpassed the Zacks Consensus Estimate by 9.2%.
The company’s GAAP earnings per share were $5.13, up 43.7% from last year’s reported figure.
CHE’s Q2 Revenues
Revenues in the reported quarter totaled $673.3 million, up 8.8% from the year-ago quarter’s figure. The metric topped the Zacks Consensus Estimate by 1.9%.
Chemed’s Raises 2026 Guidance
For 2026, the company now expects rVITAS revenue-growth guidance excluding Medicare Cap, to increase 8.25-9.25% (earlier 6.5-7.5%). The Zacks Consensus Estimate for total revenues is pegged at $2.67 billion, which indicates a 7.4% year-over-year improvement.
Adjusted EPS for the year is now expected to be in the band of $25.00-$25.75 (previously $24.00-$24.75). The Zacks Consensus Estimate for the metric is pegged at $25.00.
How Have Estimates Been Moving Since Then?
Analysts were quiet during the last two month period as none of them issued any earnings estimate revisions.
The consensus estimate has shifted 6.27% due to these changes.
VGM Scores
At this time, Chemed has a nice Growth Score of B, though it is lagging a bit on the Momentum Score front with a C. Following the exact same course, the stock has a score of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Chemed has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Chemed is part of the Zacks Medical - Outpatient and Home Healthcare industry. Over the past month, Quest Diagnostics (DGX - Free Report) , a stock from the same industry, has gained 4.2%. The company reported its results for the quarter ended June 2026 more than a month ago.
Quest Diagnostics reported revenues of $3.04 billion in the last reported quarter, representing a year-over-year change of +10.2%. EPS of $3.12 for the same period compares with $2.62 a year ago.
For the current quarter, Quest Diagnostics is expected to post earnings of $2.85 per share, indicating a change of +9.6% from the year-ago quarter. The Zacks Consensus Estimate has changed +1.1% over the last 30 days.
Quest Diagnostics has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of B.